ReviewEndocrine oncology (Bristol, England)2025
Diagnosis and management of brain metastasis from thyroid cancer.
Review in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Papillary thyroid carcinoma with brain and lung metastases: a case report.Frontiers in oncology · 2026Article
- Papillary thyroid carcinoma with metastasis to the femur as a rare cause of femoral fracture: A case report.Oncology letters · 2025Article
- Hemiparesis in a 41-Year-Old Man With Abnormal Thyroid Nodules.AACE endocrinology and diabetesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The brain is an uncommon location for metastatic spread from thyroid cancer. Given the rarity of the condition, the data regarding various management options for such patients are suboptimal. Radioactive iodine is seldom useful for brain metastases owing to variable uptake and unclear benefit. Surgical resection and stereotactic radiation remain the first-line treatment options for a limited number of brain metastases from thyroid cancer, as they not only provide local control and symptomatic relief but can also improve survival. Whole-brain radiation therapy has been used for patients with multiple brain metastases but has largely fallen out of favor due to the availability of more targeted and tolerable options. Systemic therapy with kinase inhibitors is a novel and promising area of research in this field, with an increased utilization of molecular testing to identify targetable mutations. Treatment plans for patients with brain metastases from thyroid cancer should be highly individualized and tailored to the specific patient by a multidisciplinary care team.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.